Kintara reports Q3 FY2023 net loss of $3.3M; cash at $3.0M; GBM data expected by year-end

TuHURA Biosciences, Inc./NV

Net loss $3.3M ($1.94 per share) vs. $5.4M ($5.45) in prior-year quarter; R&D spending down 42%.
Cash and cash equivalents $3.0M as of March 31, 2023; working capital $3.2M.
Top-line data from registrational GBM AGILE study for VAL-083 expected before end of calendar 2023.
Case study data from expanded access program for VAL-083 presented at AACR; REM-001 program paused to conserve cash.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2023 results: net income net loss of approximately $3.3 million, EPS $1.94 per share.

Period: fiscal third quarter ended March 31, 2023
Net income: net loss of approximately $3.3 million
EPS: $1.94 per share
Result: reported results

Exact text from the filing

For the three months ended March 31, 2023, Kintara reported a net loss of approximately $3.3 million, or $1.94 per share, compared to a net loss of approximately $5.4 million, or $5.45 per share, for the three months ended March 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TuHURA Biosciences, Inc./NV reported the nine months ended March 31, 2023 results: net income net loss of approximately $11.3 million, EPS $7.32 per share.

Period: the nine months ended March 31, 2023
Net income: net loss of approximately $11.3 million
EPS: $7.32 per share
Result: reported results

Exact text from the filing

For the nine months ended March 31, 2023, Kintara reported a net loss of approximately $11.3 million, or $7.32 per share, compared to a net loss of approximately $17.2 million, or $22.39 per share, for the nine months ended March 31, 2022.

View on SEC.gov

9 earnings releases filed in the last 30 days. Browse all earnings releases →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-23-020871

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.